Ensartinib Market Report 2026

The ensartinib market size has grown rapidly in recent years. It will grow from $1.09 billion in 2025 to $1.21 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing incidence of alk-positive lung cancer, limitations of first-generation alk inhibitors, expansion of oncology specialty clinics, growth in molecular diagnostic testing, rising awareness of targeted cancer therapies.

The ensartinib market size is expected to see rapid growth in the next few years. It will grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to expansion of biomarker-driven treatment approaches, increasing approvals for targeted oncology drugs, rising demand for second- and third-line cancer therapies, growing investment in precision medicine research, increasing focus on improving patient survival outcomes. Major trends in the forecast period include increasing adoption of next-generation alk inhibitors, rising focus on precision oncology treatments, growing use of targeted therapy in resistant nsclc cases, expansion of personalized cancer treatment protocols, enhanced clinical monitoring of treatment outcomes.

The rising incidence of lung cancer is expected to drive the growth of the ensartinib market in the coming years. Lung cancer is a disease in which abnormal cells in the lungs grow uncontrollably, often forming tumors that disrupt normal breathing and may spread to other parts of the body. The occurrence of lung cancer is rising due to prolonged exposure to air pollution, especially fine particulate matter that damages lung tissue over time. Ensartinib aids in treating lung cancer by inhibiting the abnormal activity of the ALK gene, which helps regulate tumor growth in patients with ALK-positive non-small cell lung cancer. For example, in June 2025, according to the Centers for Disease Control and Prevention, a US government agency, the number of new lung cancer cases in the United States increased from 218,893 in 2022 to 238,340 in 2023. Therefore, the rising incidence of lung cancer is fueling the growth of the ensartinib market.

The rising healthcare expenditure is anticipated to drive the growth of the ensartinib market in the coming years. Healthcare expenditure refers to the total funds spent by individuals, organizations, or governments on medical services, public health initiatives, medications, and other activities aimed at maintaining or enhancing health. Healthcare spending is increasing as the aging population requires more frequent and specialized medical care, resulting in higher overall healthcare costs. Healthcare expenditure facilitates the use of ensartinib by providing funding for advanced cancer treatments and supporting their availability in medical facilities. For example, in April 2025, according to the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, health spending in the U.S. increased by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person, representing a significant rise compared to the 4.6% growth recorded in 2022. Thus, the growing healthcare expenditure is driving the expansion of the ensartinib market.

Major companies operating in the ensartinib market are concentrating on securing regulatory approvals to expand patient access in key global markets and obtain label extensions that support additional ALK-positive NSCLC indications. Regulatory approvals are the official authorizations from health authorities that permit a drug, such as ensartinib, to be marketed and prescribed after demonstrating its safety, efficacy, and quality. For example, in December 2024, Xcovery Holdings, Inc., a US-based biopharmaceutical company, obtained FDA approval for ensartinib (marketed as Ensacove) for treating adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who had not previously received an ALK inhibitor. The approval was based on the phase 3 eXALT3 trial, in which ensartinib showed a substantial improvement in progression-free survival compared to crizotinib (median 25.8 vs 12.7 months), although overall survival was similar between the groups. Ensartinib is a second-generation ALK inhibitor developed to overcome resistance and target abnormal ALK proteins, with common side effects including rash, muscle pain, constipation, cough, itching, nausea, swelling, fever, and fatigue.

Major companies operating in the ensartinib market are Xcovery Holdings Inc., Betta Pharmaceuticals Co. Ltd.

North America was the largest region in the ensartinib market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ensartinib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ensartinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the ensartinib market by increasing costs associated with imported active pharmaceutical ingredients, specialized intermediates, clinical trial materials, and advanced manufacturing equipment. Pharmaceutical production hubs in North America and Europe are most affected due to reliance on cross-border api supply chains, while Asia-Pacific faces export-related pricing pressures. These tariffs are increasing manufacturing and distribution costs and impacting drug pricing strategies. However, they are also encouraging localized api production, regional manufacturing partnerships, and supply chain diversification to ensure long-term availability of targeted oncology therapies.

The ensartinib market research report is one of a series of new reports that provides ensartinib market statistics, including ensartinib industry global market size, regional shares, competitors with a ensartinib market share, detailed ensartinib market segments, market trends and opportunities, and any further data you may need to thrive in the ensartinib industry. This ensartinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ensartinib is a targeted cancer therapy administered orally that acts as a tyrosine kinase inhibitor, specifically inhibiting the activity of the anaplastic lymphoma kinase (ALK) protein, which is crucial in the uncontrolled growth and spread of certain cancer cells. It is primarily used for patients with ALK-positive non-small cell lung cancer, especially those who have developed resistance or intolerance to earlier-generation ALK inhibitors, helping to slow tumor progression and enhance clinical outcomes.

The primary forms of ensartinib are oral and injectable. Oral ensartinib refers to the version of the drug taken by mouth, typically as tablets or capsules. It is used across different patient groups, including pediatric, adult, and geriatric patients, for various conditions, such as non-small cell lung cancer (NSCLC), other types of lung cancer, and potential new indications. It covers different lines of treatment, including first-line, second-line, third-line and beyond, and serves end users such as hospitals, specialty clinics, and others.

The ensartinib market consists of sales of ensartinib capsules, tablets, liquid formulations, prefilled syringes, and lyophilized powder. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.